ZN-c3

DRUG4 trials

Sponsors

Zentera Therapeutics HK Limited, M.D. Anderson Cancer Center, K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Conditions

Acute Myeloid Leukemia (AML)Breast CancerLung CancerMetastatic Colorectal CancerOvarian CancerPancreatic CancerSolid TumorsTumors

Phase 1

A Phase 1b Study of ZN-c3 in Chinese Subjects

Zentera Therapeutics HK LimitedSolid Tumors

Start: 2021-07-15End: 2023-06-30Target: 38Updated: 2021-09-05

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

WithdrawnNCT05431582

M.D. Anderson Cancer CenterBreast Cancer, Lung Cancer, Ovarian Cancer +2

Start: 2022-12-14End: 2022-12-14Updated: 2023-06-15

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

TerminatedNCT05682170

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Acute Myeloid Leukemia (AML)

Start: 2022-12-01End: 2024-07-26Updated: 2024-09-19

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

TerminatedNCT05743036

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncMetastatic Colorectal Cancer

Start: 2023-02-27End: 2025-07-09Updated: 2025-08-08

Related Papers

Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated <i>BRAF V600E</i> mutantmetastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2025-05-28

Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia

Blood2023-11-02

A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).

Journal of Clinical Oncology2023-06-01